Inhibition of platelet factor 3 availability by prostacyclin.
Preincubation of human platelet rich plasma with PGI2 in a concentration preventing collagen induced platelet aggregation abolished also platelet factor 3 availability brought about by collagen. Following PGI2 pretreatment no second wave aggregation could be elicited by ristocetin. However, primary aggregation as well as platelet factor 3 activity were only partially inhibited in this case and the inhibitory action of PGI2 was not increased by raising its concentration. Similarly, marked but not complete inhibition of platelet factor 3 availability was obtained when kaolin was used as activating agent.
D001779:Blood Coagulation Factors / Q000502:physiology*; D001792:Blood Platelets / Q000187:drug effects*; D003094:Collagen / Q000494:pharmacology; D011464:Epoprostenol / Q000494:pharmacology*; D006801:Humans; D007616:Kaolin / Q000494:pharmacology; D007700:Kinetics; D010974:Platelet Aggregation / Q000187:drug effects; D010977:Platelet Factor 3 / Q000502:physiology*; D011453:Prostaglandins / Q000494:pharmacology*; D012310:Ristocetin / Q000494:pharmacology
D001779:Blood Coagulation Factors; D011453:Prostaglandins; D012310:Ristocetin; D007616:Kaolin; D010977:Platelet Factor 3; D003094:Collagen; D011464:Epoprostenol